2',3'-Dideoxycytidine

Name	2',3'-Dideoxycytidine
Alias	zalcitabine; Dideoxycytidine; ddCyd
CAS  No.	7481-89-2
Formula	C9H13N3O3
Weight	211.221 g/mol
Usage	Pharmaceuticals/Intermediates
Appearance	White powder

Analysis Of Product

Tests	Specifications	Results
Assay (HPLC)	＞98%	98.80%
Flash Point	204.8ºC	Conform
Boiling Point	415ºC at 760 mmHg	Conform
Relative Density	1.57 g/cm3	Conform
Melting Point	210-218 ºC	216 ºC
Refractive Index	78 ° (C=0.5, H2O)	Conform

A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.

PHYSICAL DESCRIPTION: White crystalline powder. Odorless. 

Zalcitabine (2′-3′-dideoxycytidine, ddC), also called dideoxycytidine, is a nucleoside analog reverse transcriptase inhibitor (NRTI) sold under the trade name Hivid. Zalcitabine was the third antiretroviral to be approved by the Food and Drug Administration (FDA) for the treatment of HIV/AIDS. It is used as part of a combination regimen.

Zalcitabine appears less potent than some other nucleoside RTIs, has an inconvenient three-times daily frequency and is associated with serious adverse events. For these reasons, it is now rarely used to treat human immunodeficiency virus (HIV), and it has even been removed from pharmacies entirely in some countries.